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Clinical pathologies draw us to envisage disease as either an independent entity or a diverse set of traits governed
by common physiopathological mechanisms, prompted by environmental assaults throughout life. Autoimmune
diseases are not an exception, given they represent a diverse collection of diseases in terms of their demographic
profile and primary clinical manifestations. Although they are pleiotropic outcomes of non-specific disease genes
underlying similar immunogenetic mechanisms, research generally focuses on a single disease. Drastic technologic
advances are leading research to organize clinical genomic multidisciplinary approaches to decipher the nature of
human biological systems. Once the currently costly omic-based technologies become universally accessible, the
way will be paved for a cleaner picture to risk quantification, prevention, prognosis and diagnosis, allowing us to
clearly define better phenotypes always ensuring the integrity of the individuals studied. However, making accurate
predictions for most autoimmune diseases is an ambitious challenge, since the understanding of these pathologies
is far from complete. Herein, some pitfalls and challenges of the genetics of autoimmune diseases are reviewed,
and an approximation to the future of research in this field is presented.
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Translational medicineIntroduction
The everlasting vision of a predictive and preventive
framework for disease assessment has pushed the med-
ical sciences to search for new means to manage health
care and translate basic research into clinical practice.
However, as we dig deeper into the cell and disease
mechanisms, the path is not always clear because each
new achievement and tool leads to more intricate defini-
tions and targets [1]. Likewise, the cost and configur-
ation of health care plans do not take into consideration
the move towards personalized medicine, due in part to
the lack of interaction between basic and clinical re-
search. Advances in technology are now prompting this
interaction, preparing for more realistic bench to bedside
implementation [1-3].
The lack of pathognomonic diagnostic tools and clear-
cut diagnostic criteria for complex conditions exposes
patients to a bureaucratic limbo, stuck in the system in
search of an accurate and complete diagnosis to receive
appropriate treatment. Clinical pathologies lead us to* Correspondence: juan.anaya@urosario.edu.co
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distribution, and reproduction in any mediumconsider disease as either an independent entity or a
diverse set of traits governed by common physiopatho-
logical mechanisms that are prompted by environmen-
tal assaults throughout life [4,5]. Autoimmune diseases
(ADs) are not an exception. Though the damage to tissues
and organs arising from the loss of tolerance is the com-
mon attractor to ADs, they represent a diverse collection of
diseases defined by their demographic and epidemiological
profile, genetic configuration of susceptibility, environmen-
tal spectrum and clinical manifestations [4]. Although
research more often focuses on a single disease (phenotype),
autoimmune phenotypes could represent heterogeneous
outcomes of genes underlying similar immunogenic
mechanisms, by either cross-phenotype association or
by pleiotropy [4,6]. In this sense, clinical observations
indicate the possible shift from one disease to another,
or the fact that more than one AD may coexist in a single
patient (that is, polyautoimmunity) or in the same family
(that is, familial autoimmunity) [7].
This article provides a glimpse of the current and
future directions for autoimmunity and ADs, discussing
the many variables affecting the potential use and appli-
cation of genetic, evolutionary, demographic, environ-
mental and immunopathological information that couldntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ment of ADs.
The genetic component of ADs
As multifactorial conditions, ADs develop from the cu-
mulative effect of diverse events on the immune system.
It is now clear they do not begin at the time of clinical
appearance but rather many years before (Figure 1). This
window of clinical silence offers the possibility of predicting
ADs [8].
Familial aggregation is observed in ADs, but the preva-
lence in close relatives of affected individuals is usually
lower than would be expected if these conditions were
Mendelian-like [9]. Recurrent associations have been
reported in the literature [10-12]. The diseases of this
aggregated pattern share similar genetic risk factors,
including the major histocompatibility complex and
also non-major histocompatibility complex variants [13-15]
(Figure 2). A higher concordance rate of ADs in monozy-
gotic than in dizygotic twins supports a significant effect
of genes additively contributing to autoimmunity [16].
Although there is higher concordance in monozygotic
twins, environment, stochastic phenomena and exposure
still result in discordance in disease thresholds among such
twin pairs [17]. Reported heritability, based on available
twin concordance rates and prevalence estimated for ADs
as a group, ranges from 0.008 for systemic sclerosis to 1.0
for Crohn’s disease, with a median value close to 0.6 [18].
ADs are not inherited in a classical Mendelian pattern, but
instead have a complex, yet incompletely defined mode ofHERITABLE 
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TCR, T cell receptor.inheritance [19-21]. Further study is needed on environ-
mental and epigenetic factors to clarify their role and effect
to allow a greater understanding of their influence, along
with genetics, in defining the onset and progression of ADs.
The National Institute of Environmental Health Sciences
through expert panel workshops has started revisions of
such factors to support this growing field of autoimmunity
research [22]. For instance, exposure to organic solvents
has been shown to affect the risk to develop ADs [23].
Age remains an important topic in autoimmunity, not
only because of the biological implications of aging on the
immune system but also because of the setback it consti-
tutes for epidemiologic studies [27]. Further complications
arise when two diseases are so far apart at their time of
diagnosis that a rigorous follow-up becomes imperative to
find co-occurrence in one patient [28].
The reason for a major prevalence of ADs among
women is poorly understood. The more frequent the AD
and the later it appears, the more women are affected
[29]. The most convincing explanation of female-biased
autoimmunity remains the hormonal theory. Hormones
such as estrogens and prolactin have been studied for
increasing susceptibility to ADs and can affect both
innate and adaptive immune systems [29]. Generally,
women have a stronger humoral and cellular immune
response than men.
In complex traits, allelic architecture challenges the
identification of common and rare genomic variants and
their potential effect on risk or protection to develop
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Figure 2 Weighted list created from the reported significant mapped genes in the current genome-wide association studies curated
from the National Human Genome Research Institute and the database of genotypes and phenotypes. The word cloud shows the
frequency of genes and its associated variants relative to their font size using a freely available java applet [24]. Both databases (accessed April 2013)
[25,26] were queried taking into account P-values reported for the genetic variants associated with autoimmune disease. For the National Human
Genome Research Institute, a total of 12,064 genetic variants were encountered, out of which 1,370 were variants significantly associated with
autoimmune disease susceptibility. In the database of genotypes and phenotypes, out of 31,246 reported variants, 972 were mutually exclusive from
the National Human Genome Research Institute, for a grand total of 2,342 genetic variants related to genes associated in a genome-wide association
study of any population. The autoimmune diseases of interest were autoimmune thyroid disease, Behcet’s disease, celiac disease, rheumatoid arthritis,
inflammatory bowel disease, juvenile rheumatoid arthritis, Kawasaki disease, multiple sclerosis, primary biliary cirrhosis, primary sclerosing cholangitis,
psoriasis, systemic sclerosis, systemic lupus erythematosus, type 1 diabetes and vitiligo.
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ADs (that is, association or linkage approaches such as
family-based co-segregation analysis) [9,15]. For association
studies, two approaches are available: genome-wide asso-
ciation studies (GWAS) and candidate gene studies. The
genome-wide association approach is usually hypothesis-
free whereas the candidate gene is hypothesis-driven.
A leap forward towards the recognition of more genes
coincided with the advent of high-throughput genotyping
technologies and genetic variation repositories, which
allowed the use of large sample cohorts to screen for
new variants. GWAS interrogate the vast majority of
known common polymorphisms [30,31]. This strategy
led to a broad array of studies of different AD cohorts
(Figure 3), aiming to disclose either new genes or loci
associated with ADs or to replicate previously reported
associations (Figure 2). Guidelines for the design, quality
control and interpretation of GWAS have been presented
elsewhere [32-34], as well as novel approaches to study
shared genetic factors (for example, cross-phenotype
meta-analysis) [35,36].
The overreaching conclusion after the first round of
GWAS reports is that genetic heterogeneity, epistasis
and complex interactions, plus demographic and environ-
mental factors, underpin the susceptibility to ADs [13-15].It is unclear how many genetic variants are associated
with ADs, and what the immunomolecular mechanisms
underlying epistasis among them are. However, a full
inventory of variants is not far away and new approaches
to examine epistasis will tell us how genes interact to con-
fer either susceptibility or protection against ADs [37]. On
top of this genetic view, newly published and publicly
available data (for example, exome sequencing project,
HapMap and the 1000 genomes project) are at par with
technological approaches probing other omic layers
like gene expression (for example, RNA-seq, Ribo-seq),
methylation (for example, Methyl-seq; BS-seq, Bisulfite
Sequencing), other epigenetic marks (for example,
ChIP-seq, Chromatin Immunoprecipitation sequencing;
FAIRE-seq, formaldehyde-assisted isolation of regulatory
elements–sequencing) and genome structure (for example,
Immuno-seq; PhIT-Seq, phenotypic interrogation via tag
sequencing) [38] are gaining further attention and applica-
tion to be compared and matched between their omic
counterparts. Current ongoing approaches mapping genetic
variation contributing to transcriptional variation, referred
to as expression quantitative trait locus analyses [39,40], are
assessing the role of genetic variants on the expression of
genes in their vicinity; empirically, these approaches have
been demonstrated to be well-powered to detect regulatory
Figure 3 Histogram showing the percentage of autoimmune diseases with significant reported genetic variants in the current genome-wide
association studies curated from the National Human Genome Research Institute and the database of genotypes and phenotypes. Both
databases [25,26] were accessed in April 2013. AITD, autoimmune thyroid disease; BD, Behcet’s disease; CD, celiac disease; IBD, inflammatory bowel disease;
JRA, juvenile rheumatoid arthritis; KD, Kawasaki disease; MS, multiple sclerosis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; PSO,
psoriasis; RA, rheumatoid arthritis; SCL, systemic sclerosis; SLE, systemic lupus erythematosus; SSC, systemic sclerosis; T1D, type 1 diabetes; VIT, vitiligo.
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to current knowledge and provide new insights for mech-
anism and molecular processes for specific phenotyped
cells and traits related to the autoimmunity phenomena.
Pitfalls and challenges of complex trait analysis
In recent years, a plethora of new susceptibility genetic
variants for ADs has emerged. The advent and advance of
microarray and next-generation sequencing technologies
has resulted in commercially available tools to provide
and obtain genotypes and sequencing information in a fast
but costly manner. This exponential production of data is
reflected in the number of manuscripts reporting associa-
tions of hundreds of loci to ADs. Thus far, the human
leukocyte antigen locus has disclosed the strongest asso-
ciation with ADs [43]. In the case of systemic lupus
erythematosus, a simple search in PubMed reported more
than 5,000 papers on the genetics of the disease. These de-
scribe more than 40 loci, replicated by several independ-
ent studies, that modify the risk to acquire the disease.
However, these systemic lupus erythematosus-associated
loci explain a minimal portion of the additive heritability,
challenging the idea that this new genetic knowledge might
allow for a better predictive and preventive assessment of
ADs (that is, missing heritability). Table 1 summarizes
the main pitfalls and challenges of complex trait analyses,
which we will comment upon next.
Two major challenges in studying ADs are the genetic
heterogeneity, referring to how a set of genetic variantsmight define a trait onset either by their combination or
differential effect, and pleiotropy [6], where a single gene
leads to multiple phenotypic expressions or disorders. As
mentioned by Lehner [44], the sharp statement by Sewal
Wright in the 1930s that ‘each character is affected by
many characters…’ is very much true today.
Diverse human populations present different allelic and
genotype structures depending upon their evolutionary and
epidemiological history [45]. In addition, the effects of
genotype on phenotype for any given population may de-
pend on the environment and length of exposure to an un-
defined etiological insult. Differences in allele and genotype
frequencies among populations reflect the contribution of
evolutionary forces such as selection, genetic drift, mutation
and migration [46], which might explain why some risk
alleles to autoimmunity may be protective factors to in-
fectious diseases and vice versa [47]. Immune and infec-
tious agents have been recognized as among the strongest
selective pressures for natural populations [47]. Further
research regarding exploration of the interplay between
infection, type of exposure, additional environmental factors
(for example, microbioma) and autoimmunity will result in
the discovery of multiple factors underpinning perhaps
newly identified physiopathology mechanisms of ADs.
The relatively short evolutionary time since the rise of
modern humans after the clash of cultures in America
(500 years) is a perfect scenario to dissect specific im-
munity associated with infectious diseases and its role in
predisposition to ADs. Classical examples are Chagas’
Table 1 Pitfalls and challenges of complex trait analysis
Pitfall and challenge Perspective
Complex epistatic interactions - Better algorithms and control for phenotype and subphenotype studies. Data analysis is the next
most expensive tool to develop.
Genetic heterogeneity - Larger size cohorts.
Pleiotropy - Familial studies to control for environmental and stochastic factors.
History of mutations and difference in
allele frequencies.
- Description and study of population genetic structure in light of reported information from other
reported and publicly available data.
Population stratification - Usage of newly reported algorithms for admixture analysis and pan-meta-analysis approaches.
Genetics in admixed populations
Statistical power and sample size - Correspondence in the use of specific clinical criteria or diagnostic biomarkers to define
phenotypes to enhance prediction and diagnosis.
Refining the phenotype - subphenotypes Development and application of bioinformatical approaches to classify disease as quantitative and
categorical entities.
Family based studies versus case–control studies Application of classical genetic and epidemiological tools to characterize new information available
for other ‘omic’ layers in the context of the genome from a familial and population viewpoint.
Gene-environment interaction Further research in environmental factors that might influence onset of disease
(for example, tobacco, coffee consumption, organic solvents)
Post-genomic era (‘omics’) Use of the publicly available ‘omic’ information already reported (for example, ENCODE, GEO, HapMap,
1000 genomes project) to explore, replicate and hypothesize new experimental functional designs.
Personalized medicine Genomic medicine-generated information to be applicable from the bench to bedside and also
from the bedside to bench.
Pharmacogenomics Disentangle markers capable of predicting and diagnosing risk of disease even before onset of
symptoms and signs.
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continents) and typhoid fever (brought to America by the
Spaniards conquers). Indeed, it is not only the knowledge
that might be contributed by this type of population, but
also the specific and direct epidemiological and health
care approach that must be provided to them. Admixed
populations such as Afro-American and Latin-American
are often medically underserved and bear a disproportion-
ately high burden of disease. Thus, given the diversity of
their genomes, these populations have both advantages
and disadvantages for genetic studies of complex pheno-
types [48]. Advances in statistical methodologies that use
genetic contributions from ancestral populations contrib-
uting to the current admixed population have proven to
be a powerful method to leverage the confounder effect of
ancestry, and this information is used to identify chromo-
somal segments linked to disease [46].
Consequently, there is a need to explore genetic associa-
tions in diverse populations. Proper matching of cases and
controls is a major consideration for GWAS, as well as in
any case–control association study. The use of ancestry
informative markers either to match or exclude cases and
controls given specific patterns of genetic stratification
allows us to overcome this limitation, diminishing the
possibility of reaching spurious associations as a conse-
quence of case–control ethnic microdifferentiation.
Determinants of statistical power such as sample size,
disease heterogeneity, pedigree and genotyping errors, as
well as the effect of the type and density of genetic markers,are a key factor in genetic studies. Studies should either
have sufficient power to detect a small effect size of mul-
tiple genes or consider the use of extreme and well-defined
phenotypes to detect the effect of major genes [30,31].
The term ‘metagenomics’ defines the set of mechanisms
by which a community of microorganisms interacts, lives
and infects animal tissues. New metagenomic approaches
have disclosed crucial information about the shaping of re-
sistance, susceptibility and loss of auto-tolerance for both
infectious and ADs [49]. Indeed, new reports demonstrate
that host-gene-microbial interactions are major determi-
nants for the development of ADs. Commensal microbial
communities may alter sex hormone levels and regulate
AD fate in individuals with a high genetic risk load [50].
Although ADs are often diagnosed according to classifi-
cation criteria, they share similar subphenotypes including
signs and symptoms, non-specific autoantibodies and high
levels of cytokines, which are prone to taxonomic problems
[51]. ADs have a heterogeneous spectrum, the disease
course differs from patient to patient and through different
phases within the same patient [52]. Refining the phenotype
will make the effect of certain genes in the sample more
easily detectable [4]. Genetic effects may be stronger for ex-
tremes of the risk factor distribution (for example, people
with onset at a very young or very old age) and for particu-
lar presentations. Therefore, restricting the sample to pa-
tients with specific characteristics, or minimizing the effect
of known environmental confounders will increase the
chances for genetic research to be successful.
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ing subphenotypes or otherwise by adjusting for known
sources of heterogeneity as a covariate. Meta-analysis and
data pooling between different research groups can provide
a sizeable study, but both approaches require a high level of
vigilance about locus and disease heterogeneity when data
come from different populations. Spurious associations are
often due to population stratification, cryptic relatedness
and differential bias [53].
GWAS have a high power to detect common variants of
high or moderate effect. For weaker effects (for example,
relative risk <1.2), the power is greatly reduced, particularly
for recessive loci if the frequency of the variant is common
(that is, rare variants) [54]. Larger size cohorts can be used
to study common diseases, but meta-analyses and data
pooling are required to attain a study size of sufficient
magnitude for many other diseases [53]. GWAS approaches
are known to be poor in detecting effects from rare alleles
(that is, frequency <5%), but novel methods and technology,
such as exome and whole genome sequencing will fill
this gap to further support the genetic commonality of
autoimmune traits [55]. However, once a polymorphism
has been found to be associated with a trait, it’s functional
relevance must be examined and its biological effect on
such a trait understood (that is, functional genomics).
Recent advances in multiplexed assay technology are
taking us closer toward the identification of ‘actionable
markers’, capable of informing and providing biological
metrics of use in clinical practice. Not only will they help
gain insights into the onset, remission and exacerbation
of a pathology, they will improve and enhance treatment,
diagnosis and classification [56].
What is next?
Genomics normally implies the use of sequence and
genome information to annotate, describe and curate
functionality and structure, in order to decipher and
disentangle functionality and organization. New ‘omics’
approaches are starting to take this further by correlat-
ing and matching layers of genome-wide information
to explain and to explore mechanisms of interaction
between genetic and environmental factors. Significant
advances in human ‘omics’ are giving rise to new possi-
bilities in medicine, such as clinical bioinformatics [57]
and translational bioinformatics [58]. All these options
lead to one common premise: ways of mining mean-
ingful information from the vast amount of ‘omics’
data being generated. In this sense, application of com-
prehensive molecular information to clinical settings is
been referred to as ‘genomic medicine’ [59] with the
ultimate goal to nurture, improve and frame personal-
ized medicine. A genomic medicine approach will al-
ways require participation at a multidisciplinary research
expertise level.Personalized medicine is committed to survey, moni-
tor and diagnose risks to provide patients with a specific
treatment, taking into account their particular genetic pro-
file and molecular phenotype. Thus evaluation, comparison,
correlation, cross-matching and interaction of the nascent
‘omic’ information would not only aid in the prediction,
diagnosis and treatment at the individual level but also
provide insights into the physiopathological mechanisms of
disease onset and progression. For such purposes, an inte-
grative personal ‘omics’ profile such as the one suggested
by Chen et al. [60] will be useful to examine as many bio-
logical components as possible. Although these compo-
nents might change during healthy and diseased states, this
information combined with genomic information will be
useful to estimate disease risk and gain new insights into
diseased states [60]. Disease would be considered as a
hierarchical biological system composed of molecular
and functional cell, tissue and organ interactive net-
works. Any aberration in one or more networks will not
only have local effects but also systemic effects because
no cell, tissue or organ is isolated or independent.
Last but not least, safeguarding for all study participants,
whether healthy or affected, and studied family members
has to be warranted. Individuals are the ‘why’ behind this
overhauling of ‘omic’ and genomics approaches and
research, thus their legal rights and status quo have to be
defined in order to eventually be successful in applying
genomic-based medicine for the benefit of human kind.
We shall not forget the understated idea ‘…we should not
only be interested in the human genome but also in the
human beings that carry it’ [61].
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